Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).

Autor:	Tuxen A; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Malmborg M; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Nouravesh N; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Videbaek L; Department of Cardiology, Odense University Hospital, Odense, Denmark., Malik M; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Zahir D; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Koeber L; Department of Clinical Medicine, University of Copenhagen, Denmark.; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark., Andersen CF; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark., Butt JH; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark., Jensen J; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark.; Department of Clinical Medicine, University of Copenhagen, Denmark., Foesbol E; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark., Andersson C; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark.; Cardiovascular Division, Brigham and Women's Hospital, Harvard School of Medicine, Boston, MA, USA., Gustafsson F; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark., Schou M; Department of Cardiology, Herlev and Gentofte University Hospital, Denmark.; Department of Clinical Medicine, University of Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	International journal of cardiology. Heart & vasculature [Int J Cardiol Heart Vasc] 2024 Jun 08; Vol. 53, pp. 101441. Date of Electronic Publication: 2024 Jun 08 (Print Publication: 2024).
DOI:	10.1016/j.ijcha.2024.101441
Abstrakt:	Background: This study investigated excess risk in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) with or without elevated levels of NT-proBNP (N-terminal pro-brain natriuretic peptide). Methods: Patients with HFrEF from the NorthStar cohort (n = 1120) were matched on age, sex, and presence of AF (atrial fibrillation/flutter) to five controls without HFrEF from The Danish National Patient Registries. Patients were compared with controls before and after stratification according to baseline NT-proBNP levels, with cutoffs defined as Results: In the HFrEF cohort, 704 patients had high NT-proBNP (median age, 73; mean left ventricular ejection fraction (LVEF), 33%). 416 patients had low NT-proBNP (median age, 65; LVEF, 30%). Patients from both groups were in NYHA class I-III. The primary endpoint occurred in 531 patients (75.4%) with HFrEF and elevated NT-proBNP, and 748 controls (21.3%) (risk difference, 54.2%; 95% confidence interval (CI) 50.7-57.6%). In comparison, it occurred in 199 patients (47.9%) with HFrEF and without elevated NT-proBNP, and 185 controls (8,9%) (risk difference, 38.9%; 95% CI 34.0-43.9%). Risk differences for all secondary endpoints were significant, except for overall mortality in the low NT-proBNP group (risk difference, 3.8%; 95% CI, -0.4-8.0%). Conclusion: This study identified a significant excess risk in patients with HFrEF across various endpoints, which persisted after stratification into high and low levels of NT-proBNP. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu